FDA approves 23 new drugs in first half, overcoming staff-cut concerns

There's an answer emerging on the multibillion-dollar question of whether the Trump administration's gutting of FDA staff in April 2025 would slow down drug approvals: So far, so good. In the

Source: Endpoints News